Shares of Terumo Corp. (OTCMKTS:TRUMY – Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $13.09, but opened at $12.6301. Terumo shares last traded at $13.02, with a volume of 42,951 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Nomura upgraded shares of Terumo to a “hold” rating in a report on Tuesday, February 24th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company has a consensus rating of “Hold”.
Check Out Our Latest Research Report on TRUMY
Terumo Price Performance
Terumo (OTCMKTS:TRUMY – Get Free Report) last issued its quarterly earnings data on Friday, February 13th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Terumo had a return on equity of 9.01% and a net margin of 11.74%.The company had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.82 billion.
Terumo Company Profile
Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.
Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.
Further Reading
- Five stocks we like better than Terumo
- “This AI Giant is About to Go Bust”
- Is Trump Done? Shocking leak…
- I tried out Elon Musk’s new AI tech — it floored me
- “I just bought 10,000 shares of a $5 stock…”
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
